Thymosin Alpha-1

Overview

Thymosin Alpha-1 is a synthetic peptide corresponding to the first 28 amino acids of prothymosin alpha, a protein naturally produced in the thymus. It is N-terminally acetylated; that acetyl group is part of the biologically active form. The compound was originally isolated in the 1970s by Allan Goldstein and colleagues at George Washington University as the substance that restored immune function in mice whose thymus had been surgically removed.

That research line led to the medicine thymalfasin, marketed as Zadaxin and registered in several countries, including China and Italy. As a result, thymosin alpha-1 has an unusually extensive clinical research record for a peptide in this database.

Caution is warranted about the precise scope of that record. Figures often cited (dozens of trials, thousands of patients) derive largely from manufacturer-affiliated reviews and are therefore difficult to verify independently. What is established is that, over several decades, research has been conducted across hepatitis B and C, sepsis, cancer, and COVID-19, and the compound is registered as a medicine in several countries.

The mechanism is broad. Thymosin alpha-1 acts on Toll-like receptors on dendritic cells. From that single point of engagement the peptide works in two directions: it can support a suppressed defence and dampen an overactive one. This two-sided, homeostasis-restoring character is what makes it scientifically interesting.

Mechanism of action

Thymosin Alpha-1 modulates the immune system primarily via TLR-2 and TLR-9 activation on myeloid and plasmacytoid dendritic cells, driving T-cell differentiation and coordinated immune activation. The peptide is N-terminally acetylated in its biologically active form and corresponds to the first 28 amino acids of prothymosin alpha.

TLR-mediated dendritic cell activation

• Binds TLR-2 and TLR-9 on myeloid and plasmacytoid dendritic cells
• Activates NF-kB and downstream signalling for cytokine production
• Stimulates IFN-alpha, IL-12, and other immunoregulatory cytokines

T-cell differentiation and activation

• Promotes differentiation of thymocytes into mature T-cells
• Increases CD4+ and CD8+ T-cell activity in immunocompromised patients
• Modulates the balance between Th1 and Th2 immune responses

Cytokine storm modulation

• Inhibits excessive CD8+ T-cell activation in inflammatory conditions
• Mitigates cytokine storm through normalisation of immune homeostasis
• In sepsis studies with immunosuppression, restoration of immune markers (such as monocyte HLA-DR expression) has been observed; whether this translates into fewer secondary infections and better survival varies between studies.

Research findings

• In clinical trials in hepatitis B patients, Ta1 showed HBV DNA clearance in 40.6% of treated patients versus 9.4% of untreated controls, a statistically significant improvement
• Combination therapy with Ta1 and interferon-alpha in hepatitis C led to normalisation of ALT levels in 71% of patients versus 35% with interferon alone
• In sepsis, results are mixed. An earlier multicentre trial (Wu 2013, n=361) showed a favourable signal on 28-day mortality that was borderline statistically significant; the largest and methodologically strongest trial to date (double-blind and placebo-controlled, n=1,106) found no difference in mortality between Ta1 and placebo (Wu 2025, TESTS). Exploratory subgroup analyses suggested possible differences by age and diabetes status, but these are hypotheses for further work, not demonstrated effects.
• Ex vivo treatment of blood cells from COVID-19 patients with Ta1 reduced cytokine storm-associated gene expression and inhibited lymphocyte activation in CD8+ T-cells
• Recent data show improvement in overall survival in patients with resectable non-small cell lung cancer in the adjuvant setting
• Ta1 serum levels are significantly reduced in patients with hepatitis B, psoriatic arthritis, multiple sclerosis, and sepsis, consistent with its role as an immunoregulator

Infectious diseases: clinical data

• Significant HBV DNA clearance in hepatitis B in randomised controlled trials
• Improved virological response in hepatitis C in combination with interferon
• In sepsis, results are mixed. An earlier multicentre study (Wu 2013, n=361) showed a favourable but borderline signal on 28-day mortality. The largest and methodologically strongest trial (double-blind, placebo-controlled, n=1,106) found no difference in mortality between Ta1 and placebo (Wu 2025, TESTS). Exploratory subgroup analyses suggested possible differences by age and diabetes status, but these are hypotheses, not demonstrated effects.

Oncology: clinical data

• Improvement in overall survival in resectable non-small cell lung cancer in adjuvant setting
• Reduction of chemoradiation-induced lymphopenia in lung cancer
• Preclinical evidence for reversal of M2 macrophage polarisation and enhancement of antitumour immunity

COVID-19 and sepsis mechanism

• Ex vivo mitigation of cytokine storm in CD8+ T-cells from COVID-19 patients
• Clinical use in COVID-19 in China as emergency treatment
• Restoration of immune markers (HLA-DR) in sepsis with immunosuppression

Research context

The combination of registration as a medicine in several countries and an extensive clinical record spanning several decades places thymosin alpha-1 at a different stage of development than most research peptides. That justifies a higher classification for research maturity, which is something different from demonstrated efficacy for every indication studied.

Clinical results are not uniform. In hepatitis C they have been mixed, and efficacy varies by indication and patient population. The most consistent signals come from populations with demonstrable immunosuppression, consistent with the immune-restorative mechanism.

Thymosin alpha-1 has one of the most extensive clinical records in this database, and the safety profile has been consistently favourable across that research. Efficacy, however, is not uniform: it varies markedly by indication and patient population. The most compelling and consistent signals come from populations with demonstrable immunosuppression, which fits the immune-restorative mechanism. In broader or immunocompetent populations the picture is mixed, and in sepsis the largest trial found no benefit. Outstanding questions therefore concern optimal use, and the populations in which the compound makes a real difference.

The 2023 FDA restriction on compounding of Ta1 in the US is a relevant regulatory signal. In the EU, Ta1 is not registered as a medicine via EMA but is available as a research compound. This distinction requires careful positioning in the European research supply market.

Open questions

Thymosin alpha-1 has one of the most extensive clinical records in this database, with a consistently favourable safety profile. Efficacy, however, varies by indication: strong and consistent in immunosuppressed populations, mixed elsewhere.

• Optimal dosing, treatment duration, and patient selection are not fully standardised
• Efficacy in immunocompetent patients is less clear than in immunocompromised populations
• Combination protocols with modern immunotherapy (checkpoint inhibitors) are still in early phase
• EU registration status as a medicine is absent; research-use positioning requires care
• Long-term data in oncological applications remain limited
• FDA compounding restriction in the US (2023) warrants monitoring for potential EU implications
• The largest randomised sepsis trial showed no mortality benefit; earlier, smaller studies were more positive. The role in sepsis is therefore uncertain.

Research outlook

Combination with checkpoint inhibitors in oncology is the most active research direction

Biomarker-guided patient selection based on Ta1 serum levels may improve treatment outcomes

Potential role in autoimmune conditions such as multiple sclerosis and psoriatic arthritis under investigation

Further work in viral respiratory infections following the COVID-19 experience

Scientific interest

TLR-mediated immune modulation

T-cell differentiation and immune reconstitution

Sepsis and infection-induced immunosuppression

Adjuvant oncological immunotherapy

Specifications

References

1. Thymosin alpha-1. · Ancell CD, Phipps J, Young L. · American Journal of Health-System Pharmacy · 2001
2. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin α1 · Li Y, Chen H, Li X, et al. · J Intensive Care Med · 2008
3. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial · Wu J, Zhou L, Liu J, et al. · Crit Care · 2013
4. Historical review of thymosin alpha 1 in infectious diseases. · Camerini R, Garaci E. · Expert Opinion on Biological Therapy · 2015
5. Immune Modulation with Thymosin Alpha 1 Treatment. · King R, Tuthill C. · Vitamins and Hormones · 2016
6. Thymosin alpha 1 treatment for patients with sepsis. · Pei F, Guan X, Wu J. · Expert Opinion on Biological Therapy · 2018
7. Serum thymosin alpha 1 levels in normal and pathological conditions. · Pica F, Gaziano R, Casalinuovo IA, et al. · Expert Opinion on Biological Therapy · 2018
8. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. · Matteucci C, Minutolo A, Balestrieri E, et al. · Open Forum Infectious Diseases · 2020
9. Identification and determination of structurally related peptide impurities in thymalfasin. · Cheng Y, Wu P, Kan Y, Li M, Li H. · Analytical and Bioanalytical Chemistry · 2022
10. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial · Wu J, Pei F, Zhou L, Guan X, et al. · BMJ · 2025

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished